Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00252 ...
Drug Name Phenytoin
Molecular Weight 252.268
Molecular Formula C15H12N2O2
CAS Number 57-41-0
SMILES O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
External Links
DRUGBANK DB00252
T3DB T3D2728
PubChem Compound 1775
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Caco-2 Permeability -4.57 - -4.57 - ADME Research, USCD
Log P 2.47 - 2.47 - HANSCH,C ET AL. (1995)
Melting Point 295.0 ℃ 295 ℃ MSDS
pKa 8.33 - 8.33 - SANGSTER (1994)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % 100.0 % PO, oral; DRUGBANK
Bioavailability 90.0 % 90±3 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 675.0 ng/ml 0-5(27%) mcg/ml Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
C Max 2250.0 ng/ml 5-10(30%) mcg/ml Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
C Max 4350.0 ng/ml 10-20(29%) mcg/ml Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
C Max 2500.0 ng/ml 20-30(10%) mcg/ml Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
T Max 2.3 h 1.5-3 h PO, oral; immediate release formulation; DRUGBANK
T Max 8.0 h 4-12 h PO, oral; extended release formulation; DRUGBANK
T Max 7.5 h 3-12 h Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
Clearance 0.25 mg/h/kg 5.9±1.2 mg/kg/day Children ↑ ;Elderly ↓ ; The Pharmacological Basis of Therapeutics
Clearance 5.7 mg/L 5.7±2.9 mg/L Children ↓ ;Elderly → ;Prem, premature ↓ ;Asian ↓ ;acute viral hepatitis AVH → ;RD, renal impairment, Renal disease，including uremia ↑ ;nephritic syndrome ↑ ;hyperthyroid, HTh → ;LTh hypothyroid → ;Somking → ; The Pharmacological Basis of Therapeutics
Clearance 0.0222 L/h/kg 0.37 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.75 L/kg 0.75 L/kg DRUGBANK
Volume of Distribution 0.64 L/kg 0.64±0.04 L/kg Apparent volume of distribution; Neonates ↑ ;acute viral hepatitis AVH → ;RD, renal impairment, Renal disease，including uremia ↑ ;hyperthyroid, HTh → ;LTh hypothyroid → ;nephritic syndrome ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.43 L/kg 0.43 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 22.0 h 22(7-42) h PO, oral; DRUGBANK
Half-life 12.5 h 10-15 h intravenous injection, IV; DRUGBANK
Half-life 15.0 h 6-24 h Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;acute viral hepatitis AVH → ;LTh hypothyroid → ;Somking → ; The Pharmacological Basis of Therapeutics
Half-life 16.8 h 16.8 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 150.0 mg/kg 150.0 mg/kg PO, oral; mouse; T3DB
Toxicity LD50 1635.0 mg/kg 1635.0 mg/kg PO, oral; Rattus, Rat; T3DB
Eliminate Route 3.0 % ~1-5 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 2.0 % 2±8 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 90.0 % ~90 % DRUGBANK
Protein Binding 89.0 % 89±23 % Neonates ↓ ;Preg, pregnant ↓ ;Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;hypoalbuminemia Alb ↓ ;acute viral hepatitis AVH ↓ ;Hepatitis, Hep ↓ ;nephritic syndrome ↓ ;Burn ↓ ;Obesity → ;Somking → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1